Skip to Content

Feline Frozen Plasma

This page contains information on Feline Frozen Plasma for veterinary use.
The information provided typically includes the following:
  • Feline Frozen Plasma Indications
  • Warnings and cautions for Feline Frozen Plasma
  • Direction and dosage information for Feline Frozen Plasma

Feline Frozen Plasma

This treatment applies to the following species:
Company: Animal Blood Resources International

NOTICE TO ALL USERS

The Package Insert is a supplement to the blood and component container labels, as the space on those labels is very limited.

No MSDS is required for these products. This Package Insert is supplied to inform the user of the product use and conform with applicable government regulations. This document should be kept on file and readily available to personnel involved in the use of these products.

Blood and blood components are biologic products and, in the form of cellular products, living feline tissue intended for use in feline patients at the discretion of the attending veterinarian. Professional judgment based on clinical evaluations determines the selection of components, dosage, the rate of administration and decisions in situations not covered in this general statement.

WARNING. In spite of serological testing, the risk of transmitting infectious agents to the patient is present. Careful donor selection, care, and available laboratory tests do not eliminate the hazard. This is especially true regarding feline viruses that do not currently have highly successful diagnostic tests and vaccination agents available. Also, septic and toxic reactions can result from transfusion of bacterially contaminated blood and components. Such reactions are rare, but may be life threatening. In addition, blood components may contain certain immunizing substances other than those indicated on the label. For example, Plasma may contain red blood cells and platelets as well as plasma. Therefore, this Package Insert as a whole or in part cannot be considered or interpreted as an expressed or implied warranty of the safety or fitness of the described blood or blood component when used for their intended purpose. Use of specific blood components as indicated by the individual patient’s clinical condition is needed to prevent inappropriate transfusion.

Autologous transfusion techniques (such as intraoperative salvage and pre-surgical donation) should be considered whenever feasible in the perioperative setting, to reduce the risks of disease transmission and immune reactions from homologous donations.

GENERAL INFORMATION

DONORS

Blood and components described in this Package Insert have been collected from feline donors which are maintained in isolated, controlled access colonies. The blood type of each donor is indicated on the product label. The colonies receive on site health care, and all animals are current on immunizations to include Rabies, Rhinotracheitis, Calici and Panleukopenia. Blood from donors maintained in controlled access colonies generally carries a lower risk of disease transmission than blood from volunteer donors. These risks for feline infectious agents cannot be eliminated under the current state of the art and it must be considered that a risk of disease transmission may be present.

Testing of Donor Blood

Testing of the donor’s blood is required before an animal is admitted into the colony as a donor and annually thereafter. All colony donors must test serologically negative for FeLV, FIV and are screened for Haemobartonella felis. The label on the container indicates whether the donor is feline blood type A, type B or type AB.

BLOOD AND COMPONENT LABELING

Labels contain the following information:

1. The name of the product.

2. The temperature range in which the component is to be stored.

3. The contents or volume (standard contents, i.e., as prepared according to this Package Insert, is assumed unless otherwise indicated on the label or in Package Insert supplements).

4. ABRI’s name, address, telephone number.

5. California Biologics registration number, if applicable.

6. The expiration date of the blood component.

7. The donor (serial) identification number.

8. Blood type of the donor

9. Statement regarding this Package Insert.

GENERAL INSTRUCTIONS FOR WHOLE BLOOD AND ALL COMPONENTS

The following general instructions pertain to Whole Blood and all the components described in this Package Insert.

● The intended recipient must be properly identified before the transfusion is started.

● The plastic blood container must not be vented.

● Blood and blood components must be administered through an appropriate blood filter. A blood administration set with standard (170-260 µ) clot filter is recommended when administering volumes greater than 50 mL. An ABRI Feline Administration set or 18 micron blood filter (HEMO-NATE® blood filter or equivalent) is recommended for volumes less than 50 mL.

● Before use, bags of blood or components should be gently rocked to thoroughly mix contents.

● No medications or solutions may be added to or infused through the same tubing with blood or components except 0.9% Sodium Chloride, Injection (USP).

● Lactated Ringer’s, Injection (USP) or other electrolyte solutions containing calcium should NEVER be administered concurrently with blood or components collected in an anticoagulant containing citrate. All of the products described below contain and are collected into anticoagulants which contain citrate.

● Hemolysis may become evident during the storage of components containing red blood cells. Blood and components should be inspected for bacterial growth. If upon visual inspection the fitness of a component is questioned because of, for example, presence of hemolysis, a significant color change in the contents of the blood bag as compared to the tubing segments, floccular material, cloudy appearance or other problems, the component should not be used. A slight pink tinge to the supernatant due to some free hemoglobin may be present and is acceptable for transfusion. Call Animal Blood Resources International at (800) 243-5759 for further evaluation.

● When thawing frozen products in a water bath, care must be taken to prevent contamination of entry ports. The use of watertight protective plastic over wraps (such as freezer bags) is recommended.

● Blood components have been prepared by techniques that aid in preserving sterility up to the time of expiration. If the container is entered in a fashion that could contaminate the contents of the container for any reason the component expires 4 hours after entry if maintained at room temperature (20° - 24° C), or 24 hours after entry if refrigerated (1° - 6° C).

● Blood and components may be warmed to no more than 37° C during transfusion, if warming is clinically indicated for situations such as hypothermia, blood exchange or massive transfusions.

● Unless otherwise indicated by the patient’s clinical condition, the rate should be slow, no greater than 0.11 mL / pound of body weight for the first 30 minutes of the transfusion. The patient should be observed during this period since some life threatening reactions occur after the infusion of only a small volume of incompatible blood. If a transfusion reaction occurs, the transfusion should be discontinued immediately and appropriate therapy initiated. The infusion should not be restarted.

● Completion of the transfusion should be prior to component expiration or within 4 hours, whichever is sooner. If blood or components cannot be infused in 4 hours, they should be divided and stored appropriately in the refrigerator until needed.

A crossmatch should be conducted before every transfusion.

● The blood type of both the donor and the recipient should be known before transfusing whenever possible. When the blood type of the recipient is not known, a crossmatch must be performed. First time transfusions with donors and recipients of unknown blood types are NEVER considered safe.

● Blood transfusions should never be considered safe, even under optimum conditions, and should not be given unless there is no other acceptable treatment.

SPECIFIC INSTRUCTIONS FOR FROZEN PLASMA

Description

Frozen Plasma (FP) consists of the anticoagulated clear portion of blood that is separated by centrifugation or sedimentation no later than 5 days after the expiration date of the Whole Blood. Frozen Plasma may be stored refrigerated for up to 5 days after the expiration date of the whole blood from which it is removed. This “freeze by” date is indicated on the plasma carton. FP contains a minimum of 25 mLs of Frozen Plasma. The range is due to differences in donor PCV’s. All non labile coagulation factors are present.

Plasma components for transfusion may be prepared from Whole Blood collected in all approved anticoagulant solutions except Heparin Solution.

Actions

FP contains plasma proteins, including non labile clotting factors such as fibrinogen, Factor VII and Factor IX. FP does not contain the labile clotting Factors V, VIII and vWf.

Feline Frozen Plasma Indications

These components are indicated for the treatment of stable clotting factor deficiencies, such as Warfarin poisoning, and plasma protein deficiencies. Note: Plasma is not the first treatment of choice for volume expansion. See contraindications.

Contraindications

Do not use FP when coagulopathy can be corrected more effectively with specific therapy, such as vitamin K. Do not use FP for re-placement of labile coagulation factors such as Factors V and Vlll, including vonWillebrand’s factor (vWf). Do not use these components when blood volume can be safely and adequately replaced with other volume expanders such as 0.9% Sodium Chloride, Injection (USP) or Lactated Ringer’s, Injection (USP).

Side Effects and Hazards

As described for Whole Blood, side effects and hazards may include febrile, hemolytic and allergic reactions; circulatory overload; and transmission of infectious diseases. If massive volumes of plasma are used, citrate toxicity, hypothermia and other metabolic problems may occur. Antibodies in the plasma may react with the recipient’s red cells, causing a positive direct antiglobulin test, possibly hemolysis and, rarely, non-cardiogenic pulmonary edema.

Dosage and Administration

FP should be used as soon as possible but no more than 24 hours after thawing (stored at 1° - 6° C) when administered as a source of labile coagulation factors. Frozen plasma thawed and maintained at temperatures of less than 45° F may be refrozen as long as closed system has not been breached.

REFERENCES

A reference list is available upon request from Animal Blood Re-sources International, or on our website, www.abrint.net

Animal Blood Resources International

www.abrint.net

info@abrint.net

(800) 243-5759

Summary Chart of Blood Components

Component

Major Indications

Action

Not Indicated For

Special Hazards

Rate of Infusion

Frozen Plasma

Deficit of non labile coagulation factors

Source of non labile factors

Deficit of labile coagulation factors or volume replacement

Infectious diseases, allergic reactions, circulatory overload

Less than 4 hours

© Copyright 2013 - Animal Blood Bank, All Rights Reserved

CPN: 1398003.3

ANIMAL BLOOD RESOURCES INTERNATIONAL
P.O. BOX 609, STOCKBRIDGE, MI, 49285
Telephone:   800-2HELPK9 (800-243-5759)
Fax:   517-851-7762
Website:   www.ABRInt.net
Email:   customerservice@ABRInt.net
Every effort has been made to ensure the accuracy of the Feline Frozen Plasma information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2019 Animalytix LLC. Updated: 2019-09-30

Hide